Doctors rely on specific blood tests to check how well the clotting system is working, particularly in patients on ...

Emicizumab, a bispecific antibody that bridges clotting factors IX and X, restores factor VIII function and prevents bleeding in hemophilia A with infrequent injections.

Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA) 2026 ESC/European Renal ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Hannia Zia and Joana Ferreira, founders of Cascade, are shaking up the construction industry ...

Patrick Muldoon's death certificate revealed he was dealing with hereditary coagulopathy disorder, a type of blood disorder, that contributed to his passing. "If you have a clotting disorder, your ...

Blood coagulation factor XIII (FXIII) is the final transglutaminase in the clotting cascade, responsible for cross-linking fibrin polymers and stabilising the haemostatic plug. In plasma it circulates ...

Researchers at McGill University have developed a rapid way to engineer blood clots that stop severe bleeding and support tissue healing more effectively. Their technique, called “click clotting,” ...

A large international study has found that asundexian, an investigational anti-clotting medication, reduces the risk of a stroke in people who recently experienced a stroke or transient ischemic ...

Researchers have uncovered why a rare blood clotting disorder can occur after certain COVID-19 vaccines or adenovirus infections. The immune system can mistakenly target a normal blood protein (PF4) ...

At some point in our EMT and paramedic training, we learned how dangerous hemophilia and other bleeding disorders can be for trauma patients. We also learned there was not much we could do for them in ...

Bayer can report a success in stroke treatment, even though an earlier study with the same compound had been discontinued due to limited benefit. The approach of inhibiting factor XIa represents a ...

NEW ORLEANS, Feb. 5, 2026 — An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic (clot-caused) stroke without raising bleeding concerns, ...